Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion and absolute bioavailability in healthy participants.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13524
Abstract: This single-center, open-label, non-randomized, two-part, phase I study was conducted 1) to evaluate the absolute oral bioavailability of rilzabrutinib 400 mg tablet following an IV microtracer dose of ~100 μg [14C]-rilzabrutinib (~1 μCi) and single… read more here.
Keywords: rilzabrutinib; excretion; oral dose; absolute bioavailability ... See more keywords